SCHEMBL14068673

SCHEMBL14068673

CNC(=N)SCc1ccccc1Sc1ccccc1CSC(=N)NC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IFNAR1 P17181 1/20 0.44
LMNA P02545 5/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RECQL P46063 2/20 0.39
SLC6A2 P23975 4/20 0.38
SLC6A4 P31645 4/20 0.38
HTT P42858 3/20 0.38
IDO1 P14902 2/20 0.38
TAAR1 Q96RJ0 2/20 0.38
ALDH1A1 P00352 2/20 0.36
MAPK1 P28482 2/20 0.36
NPY1R P25929 1/20 0.36
NPY2R P49146 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GFER P55789 1/20 0.36
SLC6A3 Q01959 2/20 0.36
HPGD P15428 2/20 0.36
PRMT1 Q99873 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3693564 0.87 TAAR1 (0.38) IFNAR1LMNASMN1; SMN2RECQLSLC6A2
SCHEMBL22275634 0.87 IDO1 (0.43) LMNASMN1; SMN2HTTIDO1TAAR1
SCHEMBL3693561 0.86 NOS1 (0.44) IFNAR1LMNASMN1; SMN2HTTIDO1
Bromide SCHEMBL4446848 0.86 TAAR1 (0.37) IFNAR1LMNASMN1; SMN2RECQLSLC6A2
Hydrochloric Acid SCHEMBL22263158 0.85 IDO1 (0.44) LMNASMN1; SMN2HTTIDO1TAAR1
Bromide SCHEMBL4446847 0.85 NOS1 (0.43) IFNAR1LMNASMN1; SMN2HTTIDO1
SCHEMBL3684582 0.83 IDO1 (0.41) IFNAR1LMNASMN1; SMN2RECQLSLC6A2
Bromide SCHEMBL4440779 0.81 IDO1 (0.40) IFNAR1LMNASMN1; SMN2RECQLSLC6A2
SCHEMBL20932610 0.81 IDO1 (0.39) LMNASMN1; SMN2SLC6A2SLC6A4HTT
SCHEMBL3684271 0.77 IDO1 (0.62) LMNASMN1; SMN2HTTIDO1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 IFNAR1 3372/4885LMNA 1202/4885SMN1; SMN2 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.